 |
Arteria LabAdvanced Therapeutic for metabolic diseasesARTERIA is a French Biopharmaceutical Company dedicated to the development of novel small New Chemical Entities for patients affected by metabolic diseases and Type II Diabetes. The company primary focus is the inhibition of atherosclerotic plaque growth and instability, insulin resistance, glucose intolerance, and lipotoxic cardiomyopathy. ARTERIA is currently completing the preclinical studies of a new series of products, designed to treat patients with atherogenic dyslipidemia. Back-up molecules, achieving similar efficacy for preventing the growth of atherosclerotic plaque are also beeing identified.
|